Athenex announces publication of data from phase 3 study comparing oral paclitaxel plus encequidar versus intravenous paclitaxel in patients with metastatic breast cancer in the journal of clinical oncology

Buffalo, n.y., july 25, 2022 (globe newswire) -- athenex, inc., (nasdaq: atnx), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the publication of their manuscript, “open-label, randomized, multicenter, phase iii study comparing oral paclitaxel plus encequidar versus intravenous paclitaxel in patients with metastatic breast cancer”. the article, along with results, can be found on the american society of clinical oncology journal's website at this link.
ATNX Ratings Summary
ATNX Quant Ranking